Spots Global Cancer Trial Database for A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Official Title: A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF INOTUZUMAB OZOGAMICIN IN CHINESE ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Study ID: NCT05687032
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, single-arm, multicenter study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in patients with relapsed or refractory B-cell ALL from mainland China.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking University First Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijing, Beijing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The First Hospital of Harbin, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, China
Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China
Wuhan Tongji Hospital, Wuhan, Hubei, China
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The First Hospital of Jilin University, Changchun, Jilin, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
The first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
